Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quarterly results round-up: Baxter weighed down by unfavourable exchange rates; BIM, ISRG, LH, NVS

This article was originally published in Clinica

Executive Summary

Like its peers Johnson & Johnson and Abbott, Baxter International's top line has been dented by foreign exchange rates: Baxter reported second-quarter revenues of $3.6bn, up 4% on a constant currency basis, but just 1% on a reported basis. Also the firm's two business units, medical products and bioscience, both grew 1% (+4% constant currency) to $2.0bn and $1.6bn, respectively.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel